Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15499257 | 0.82 | SLC6A2 (0.39) | SLC6A2SSTR4HTR1A | |
| SCHEMBL19370313 | 0.82 | SLC6A2 (0.39) | SLC6A2SSTR4HTR1A | |
| SCHEMBL15496986 | 0.82 | SLC6A2 (0.39) | SLC6A2SSTR4HTR1A | |
| SCHEMBL20078604 | 0.81 | SLC6A2 (0.38) | SLC6A2SSTR4HTR1A | |
| SCHEMBL8916691 | 0.81 | SLC6A2 (0.38) | SLC6A2SSTR4 | |
| SCHEMBL26316830 | 0.78 | SLC6A2 (0.36) | SLC6A2SSTR4HTR1A | |
| SCHEMBL22081057 | 0.78 | SLC6A2 (0.36) | SLC6A2SSTR4 | |
| SCHEMBL17409968 | 0.77 | SLC6A2 (0.39) | SLC6A2SSTR4HTR1A | |
| SCHEMBL627761 | 0.77 | SLC6A2 (0.39) | SLC6A2SSTR4HTR1A | |
| SCHEMBL19366757 | 0.77 | SLC6A2 (0.39) | SLC6A2SSTR4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | SLC6A2 2141/4885SSTR4 764/4885HTR1A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.